The therapeutic potential of nanobodies
I Jovčevska, S Muyldermans - BioDrugs, 2020 - Springer
Today, bio-medical efforts are entering the subcellular level, which is witnessed with the fast-
developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with …
developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with …
Antibody structure and function: the basis for engineering therapeutics
ML Chiu, DR Goulet, A Teplyakov, GL Gilliland - Antibodies, 2019 - mdpi.com
Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …
KDIGO 2021 clinical practice guideline for the management of glomerular diseases
BH Rovin, SG Adler, J Barratt, F Bridoux… - Kidney …, 2021 - kidney-international.org
Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …
[HTML][HTML] ISTH guidelines for treatment of thrombotic thrombocytopenic purpura
Background Despite advances in treatment options for thrombotic thrombocytopenic purpura
(TTP), there are still limited high quality data to inform clinicians regarding its appropriate …
(TTP), there are still limited high quality data to inform clinicians regarding its appropriate …
Applications of nanobodies
S Muyldermans - Annual review of animal biosciences, 2021 - annualreviews.org
Unique, functional, homodimeric heavy chain–only antibodies, devoid of light chains, are
circulating in the blood of Camelidae. These antibodies recognize their cognate antigen via …
circulating in the blood of Camelidae. These antibodies recognize their cognate antigen via …
Phage display derived monoclonal antibodies: from bench to bedside
MA Alfaleh, HO Alsaab, AB Mahmoud… - Frontiers in …, 2020 - frontiersin.org
Monoclonal antibodies (mAbs) have become one of the most important classes of
biopharmaceutical products, and they continue to dominate the universe of …
biopharmaceutical products, and they continue to dominate the universe of …
Nanobodies: next generation of cancer diagnostics and therapeutics
The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …
Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management
S Sukumar, B Lämmle, SR Cataland - Journal of clinical medicine, 2021 - mdpi.com
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy
characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and …
characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and …
[HTML][HTML] ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura
Background Despite an increase in our understandings of pathogenesis of thrombotic
thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management of …
thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management of …
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura
Background In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated
deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained …
deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained …